PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma
Authors
Keywords
-
Journal
OncoImmunology
Volume 6, Issue 2, Pages e1273309
Publisher
Informa UK Limited
Online
2017-01-04
DOI
10.1080/2162402x.2016.1273309
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
- (2016) Julien Calderaro et al. HEPATOLOGY
- Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction
- (2016) Xiao-Lei Shi et al. JOURNAL OF HEPATOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Reduced Expression of Galectin-9 Contributes to a Poor Outcome in Colon Cancer by Inhibiting NK Cell Chemotaxis Partially through the Rho/ROCK1 Signaling Pathway
- (2016) Yang Wang et al. PLoS One
- Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
- (2015) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Clinical impact of herpesvirus entry mediator expression in human hepatocellular carcinoma
- (2015) Daisuke Hokuto et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers
- (2015) Moon-Young Kim et al. LUNG CANCER
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma
- (2015) Hangcheng Fu et al. TUMOR BIOLOGY
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- PDL1 expression is an independent prognostic factor in localized GIST
- (2015) François Bertucci et al. OncoImmunology
- Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study
- (2015) André P Fay et al. Journal for ImmunoTherapy of Cancer
- PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics
- (2014) D. Massi et al. ANNALS OF ONCOLOGY
- PD-L1 expression in nonclear-cell renal cell carcinoma
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
- (2014) T. K. Choueiri et al. CLINICAL CANCER RESEARCH
- Galectin-9-CD44 Interaction Enhances Stability and Function of Adaptive Regulatory T Cells
- (2014) Chuan Wu et al. IMMUNITY
- Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies
- (2013) K. Sideras et al. CANCER TREATMENT REVIEWS
- Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
- (2013) Raoul A. Droeser et al. EUROPEAN JOURNAL OF CANCER
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells
- (2013) Sheng-Jia Shi et al. PLoS One
- Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer
- (2013) Jing Jiang et al. PLoS One
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Galectin-9 Acts as a Prognostic Factor with Antimetastatic Potential in Hepatocellular Carcinoma
- (2012) Zhao-Yang Zhang et al. Asian Pacific Journal of Cancer Prevention
- Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
- (2012) M. Platten et al. CANCER RESEARCH
- The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy
- (2012) Christine Pasero et al. CURRENT OPINION IN PHARMACOLOGY
- Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer
- (2012) Alexander Pedroza-Gonzalez et al. HEPATOLOGY
- Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
- (2012) Hang Li et al. HEPATOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma
- (2012) Elisabetta Cariani et al. PLoS One
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas
- (2011) Jie Chen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
- (2011) J. Godin-Ethier et al. CLINICAL CANCER RESEARCH
- Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
- (2011) X. Frigola et al. CLINICAL CANCER RESEARCH
- Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients
- (2011) Qiyi Zhao et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Activated CD69+ T Cells Foster Immune Privilege by Regulating IDO Expression in Tumor-Associated Macrophages
- (2011) Q. Zhao et al. JOURNAL OF IMMUNOLOGY
- Therapeutic potential of Galectin-9 in human disease
- (2011) Valerie R. Wiersma et al. MEDICINAL RESEARCH REVIEWS
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Overall survival and PD-L1 expression in metastasized malignant melanoma
- (2010) Jules Gadiot et al. CANCER
- BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination
- (2010) Laurent Derré et al. JOURNAL OF CLINICAL INVESTIGATION
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions
- (2009) K. Wu et al. CANCER RESEARCH
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
- (2009) Dong-Ming Kuang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Diagnosis and Treatment of Hepatocellular Carcinoma
- (2008) Hashem B. El-Serag et al. GASTROENTEROLOGY
- Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma
- (2008) Meiyan Liang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
- (2008) Ke Pan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started